The Maasstad Absorb Registry: Experience with the Absorb bioresorbable vascular scaffold.
Phase of Trial: Phase IV
Latest Information Update: 02 Nov 2017
At a glance
- Drugs Everolimus (Primary)
- Indications Acute coronary syndromes; Coronary artery disease; Coronary artery restenosis
- Focus Adverse reactions; Therapeutic Use
- 02 Nov 2017 Pooled results of COMPARE II, RAI and MAASSTAD-ABSORB studies, comparing the outcomes of Bioresorbable Vascular Scaffold versus a 2nd generation metallic stent in the patients with Small vessel disease presented at the 29th Annual Scientific Symposium on Transcatheter Cardiovascular Therapeutics.
- 02 Apr 2015 New trial record